| 1 |
12646262 | Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation. | 2003 Apr 1 |
1 |
| 2 |
11329882 | Inhibition of X-ray and doxorubicin-induced apoptosis by butyrolactone I, a CDK-specific inhibitor, in human tumor cells. | 2000 Dec |
1 |
| 3 |
10347813 | Induction of apoptosis in cancer cells by tumor necrosis factor and butyrolactone, an inhibitor of cyclin-dependent kinases. | 1999 Apr |
2 |
| 4 |
10500810 | Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. | 1999 |
1 |
| 5 |
9309154 | [CDK and MMP inhibitors]. | 1997 Sep |
2 |
| 6 |
9371520 | The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. | 1997 Nov 15 |
3 |
| 7 |
9398320 | MAP4 is the in vivo substrate for CDC2 kinase in HeLa cells: identification of an M-phase specific and a cell cycle-independent phosphorylation site in MAP4. | 1997 Dec 16 |
1 |
| 8 |
9042196 | Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. | 1996 Nov-Dec |
3 |